Viking Therapeutics reports Q2 EPS (58c), consensus (44c)

“The Viking team achieved significant execution and clinical milestones during the first half of 2025,” stated Brian Lian, Ph.D., chief executive officer of Viking. “With respect to our VK2735 program for obesity, we recently announced the initiation of the VANQUISH Phase 3 registration program, consisting of two studies: one in patients with obesity and one in patients with obesity and type 2 diabetes. Also during the first half of the year, we announced both the initiation and completion of enrollment in the Phase 2 VENTURE-Oral Dosing study of our oral tablet formulation of VK2735. We believe the study’s rapid enrollment speaks to continued strong demand for new and differentiated weight loss therapies. We remain on track to announce top-line data from the VENTURE-Oral study in the second half of the year. With respect to our amylin agonist program, we continue to make progress toward an IND filing, which we expect to submit later this year. Importantly, we completed the second quarter with a strong balance sheet providing the runway to support the advancement of VK2735 through Phase 3 clinical trials, in addition to supporting further progress with other key development programs.”